Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Improved Outcome of a Pediatric-Inspired Protocol for High-Risk Adolescent and Young Adult Acute Lymphoblastic Leukemia Patients Using Peg-Asparaginase and Escalating Dose of Methotrexate: Tolerability and Outcome.

Hanbali A, Kotb A, El Fakih R, Alfraih F, Ahmed SO, Shaheen M, Hashmi S, Alhayli S, Alahmari A, Riash MA, Rasheed W, Alzahrani H, Alsharif F, Chaudhri N, Almohareb F, Aljurf M.

Clin Lymphoma Myeloma Leuk. 2019 May 16. pii: S2152-2650(19)30196-X. doi: 10.1016/j.clml.2019.05.004. [Epub ahead of print]

PMID:
31377206
2.

Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study.

Huguet F, Leguay T, Raffoux E, Thomas X, Beldjord K, Delabesse E, Chevallier P, Buzyn A, Delannoy A, Chalandon Y, Vernant JP, Lafage-Pochitaloff M, Chassevent A, Lhéritier V, Macintyre E, Béné MC, Ifrah N, Dombret H.

J Clin Oncol. 2009 Feb 20;27(6):911-8. doi: 10.1200/JCO.2008.18.6916. Epub 2009 Jan 5. Erratum in: J Clin Oncol. 2009 May 20;27(15):2574. Dosage error in article text.

PMID:
19124805
3.

Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia.

DeAngelo DJ, Stevenson KE, Dahlberg SE, Silverman LB, Couban S, Supko JG, Amrein PC, Ballen KK, Seftel MD, Turner AR, Leber B, Howson-Jan K, Kelly K, Cohen S, Matthews JH, Savoie L, Wadleigh M, Sirulnik LA, Galinsky I, Neuberg DS, Sallan SE, Stone RM.

Leukemia. 2015 Mar;29(3):526-34. doi: 10.1038/leu.2014.229. Epub 2014 Jul 31.

4.

Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL).

Rytting ME, Thomas DA, O'Brien SM, Ravandi-Kashani F, Jabbour EJ, Franklin AR, Kadia TM, Pemmaraju N, Daver NG, Ferrajoli A, Garcia-Manero G, Konopleva MY, Cortes JE, Borthakur G, Garris R, Cardenas-Turanzas M, Schroeder K, Jorgensen JL, Kornblau SM, Kantarjian HM.

Cancer. 2014 Dec 1;120(23):3660-8. doi: 10.1002/cncr.28930. Epub 2014 Jul 17.

5.

Risk-Benefit Analysis of Pediatric-Inspired Versus Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Protocols for Acute Lymphoblastic Leukemia in Adolescents and Young Adults.

Guzauskas GF, Villa KF, Vanhove GF, Fisher VL, Veenstra DL.

J Adolesc Young Adult Oncol. 2017 Mar;6(1):53-61. doi: 10.1089/jayao.2016.0049. Epub 2016 Oct 25.

6.

Best Practices in Adolescent and Young Adult Patients with Acute Lymphoblastic Leukemia: A Focus on Asparaginase.

Boissel N, Sender LS.

J Adolesc Young Adult Oncol. 2015 Sep;4(3):118-28. doi: 10.1089/jayao.2015.0014. Review.

7.

Adolescents and young adults with acute lymphoblastic leukemia have a better outcome when treated with pediatric-inspired regimens: systematic review and meta-analysis.

Ram R, Wolach O, Vidal L, Gafter-Gvili A, Shpilberg O, Raanani P.

Am J Hematol. 2012 May;87(5):472-8. doi: 10.1002/ajh.23149. Epub 2012 Mar 3. Review.

8.

Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.

Place AE, Stevenson KE, Vrooman LM, Harris MH, Hunt SK, O'Brien JE, Supko JG, Asselin BL, Athale UH, Clavell LA, Cole PD, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Schorin MA, Welch JJ, Lipshultz SE, Kutok JL, Blonquist TM, Neuberg DS, Sallan SE, Silverman LB.

Lancet Oncol. 2015 Dec;16(16):1677-90. doi: 10.1016/S1470-2045(15)00363-0. Epub 2015 Nov 6.

PMID:
26549586
9.

[Adolescent and young adult Philadelphia negative B cell acute lymphoblastic leukemia: results of the Chilean protocol LLA 15-30].

Puga B, Guerra C, Molina J, Cabrera ME, Pilleux L, Calderón S, Rojas C, Vergara CG, Rojas H, Muñoz L, Lois V, Aspillaga A, Pizarro A.

Rev Med Chil. 2014 Jun;142(6):707-15. doi: 10.4067/S0034-98872014000600004. Spanish.

10.

Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen.

Rytting ME, Jabbour EJ, Jorgensen JL, Ravandi F, Franklin AR, Kadia TM, Pemmaraju N, Daver NG, Ferrajoli A, Garcia-Manero G, Konopleva MY, Borthakur G, Garris R, Wang S, Pierce S, Schroeder K, Kornblau SM, Thomas DA, Cortes JE, O'Brien SM, Kantarjian HM.

Am J Hematol. 2016 Aug;91(8):819-23. doi: 10.1002/ajh.24419. Epub 2016 Jun 30.

12.

Markedly improved outcomes and acceptable toxicity in adolescents and young adults with acute lymphoblastic leukemia following treatment with a pediatric protocol: a phase II study by the Japan Adult Leukemia Study Group.

Hayakawa F, Sakura T, Yujiri T, Kondo E, Fujimaki K, Sasaki O, Miyatake J, Handa H, Ueda Y, Aoyama Y, Takada S, Tanaka Y, Usui N, Miyawaki S, Suenobu S, Horibe K, Kiyoi H, Ohnishi K, Miyazaki Y, Ohtake S, Kobayashi Y, Matsuo K, Naoe T; Japan Adult Leukemia Study Group (JALSG).

Blood Cancer J. 2014 Oct 17;4:e252. doi: 10.1038/bcj.2014.72.

13.

Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.

Vora A, Goulden N, Mitchell C, Hancock J, Hough R, Rowntree C, Moorman AV, Wade R.

Lancet Oncol. 2014 Jul;15(8):809-18. doi: 10.1016/S1470-2045(14)70243-8. Epub 2014 Jun 9.

PMID:
24924991
14.

Comparison of a pediatric-inspired treatment protocol versus standard-intensity chemotherapy for young adults with standard-risk BCR-ABL negative acute lymphoblastic leukemia.

Kliman D, Barnett M, Broady R, Forrest D, Gerrie A, Hogge D, Nantel S, Narayanan S, Nevill T, Power M, Sanford D, Song K, Sutherland H, Toze C, Abou Mourad Y.

Leuk Lymphoma. 2017 Apr;58(4):909-915. doi: 10.1080/10428194.2016.1222376. Epub 2016 Aug 26.

PMID:
27561638
15.

The effect of adopting pediatric protocols in adolescents and young adults with acute lymphoblastic leukemia in pediatric vs adult centers: An IMPACT Cohort study.

Gupta S, Pole JD, Baxter NN, Sutradhar R, Lau C, Nagamuthu C, Nathan PC.

Cancer Med. 2019 May;8(5):2095-2103. doi: 10.1002/cam4.2096. Epub 2019 Mar 26.

16.

The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.

Güneş AM, Oren H, Baytan B, Bengoa SY, Evim MS, Gözmen S, Tüfekçi O, Karapınar TH, Irken G.

Ann Hematol. 2014 Oct;93(10):1677-84. doi: 10.1007/s00277-014-2106-0. Epub 2014 May 27.

PMID:
24863691
17.

Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96.

Ribera JM, Oriol A, Sanz MA, Tormo M, Fernández-Abellán P, del Potro E, Abella E, Bueno J, Parody R, Bastida P, Grande C, Heras I, Bethencourt C, Feliu E, Ortega JJ.

J Clin Oncol. 2008 Apr 10;26(11):1843-9. doi: 10.1200/JCO.2007.13.7265.

PMID:
18398150
19.

Adoption of pediatric-inspired acute lymphoblastic leukemia regimens by adult oncologists treating adolescents and young adults: A population-based study.

Muffly L, Lichtensztajn D, Shiraz P, Abrahão R, McNeer J, Stock W, Keegan T, Gomez SL.

Cancer. 2017 Jan 1;123(1):122-130. doi: 10.1002/cncr.30322. Epub 2016 Sep 13.

20.

Dose intensification of methotrexate and cytarabine during intensified continuation chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: POG 9406: a report from the Children's Oncology Group.

Tower RL, Jones TL, Camitta BM, Asselin BL, Bell BA, Chauvenet A, Devidas M, Halperin EC, Pullen J, Shuster JJ, Winick N, Kurtzberg J.

J Pediatr Hematol Oncol. 2014 Jul;36(5):353-61. doi: 10.1097/MPH.0000000000000131.

Supplemental Content

Support Center